SYDNEY, AUSTRALIA: BCAL Diagnostics Limited (ASX:BDX) has announced the appointment of Shane Ryan as the new CEO, effective from April 2, 2024. Ryan, previously the company’s COO, will lead the launch of the innovative breast cancer test, BREASTEST™, and drive the company’s commercialisation efforts.
Ryan’s extensive experience in biotechnology product commercialisation, notably his successful launch of a breast cancer test in 2021, positions him as the ideal leader for BCAL’s strategic market introduction and growth. The outgoing CEO, Dr. John Hurrell, will transition to a Non-Executive Director role, continuing to provide scientific and commercial guidance.
Chair Jayne Shaw expressed confidence in Ryan’s leadership at this pivotal moment, as BCAL prepares for the Australian market launch of BREASTEST™. Shaw also acknowledged Hurrell’s significant contributions to the company and his ongoing advisory role.
These executive changes align with BCAL’s strengthened leadership, including the recent addition of David Darling as Non-Executive Director and the establishment of a Clinical Advisory Board. With its strategic team in place, BCAL is poised to solidify its presence in the breast cancer diagnostics industry.